DOI: https://doi.org/10.14710/dimj.v3i2.15448

Factors Associated With Recurrence Of Epithelial Ovarian Cancer In RSUP Dr. Kariadi Semarang

*Isabela Marsialina Kurube  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Ediwibowo Ambari  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Teuku Mirza Iskandar  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Hary Tjahjanto  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Julian Dewantiningrum  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Arufiadi Anityo Mochtar  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Yuli Trisetiyono  -  Departement of Obstetric and Gynecology, Universitas Diponegoro, Indonesia
Open Access Copyright (c) 2022 Diponegoro International Medical Journal
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Introductions: Epithelial ovarian cancer accounts for 90% of all ovarian malignancies. More than 70% of patients will experience a relapse even after receiving operative therapy and chemotherapy. There are several prognostic factors that influence the recurrence of ovarian cancer. In Indonesia, especially at Dr. Kariadi Hospital, Semarang, the data as mentioned above is still very limited.

objective: Knowing the disease-free survival rate, optimizing surgery and factors related to the incidence of recurrence in epithelial ovarian cancer patients at Dr. Kariadi Hospital Semarang

Methods: This study is a retrospective cohort study with survival analysis. Data were collected through medical records, with the study population are patients with a diagnosis of epithelial ovarian cancer who were treated at Dr. Kariadi Hospital Semarang in period January 2018-December 2019. Furthermore, patients who had been remission were observed for signs of disease recurrence for 2 years period.

Results: There were 361 patients with epithelial ovarian cancer who underwent primary treatment at Dr. Kariadi Hospital, Semarang in  2018-2019. Furthermore, there were observations of recurrence in 148 patients who achieved remission. Of these 76 patients (51.4%) experienced recurrence, while 72 patients not relapse. From 148 epithelial ovarian cancer patients who underwent cytoreduction surgery at Dr. Kariadi Hospital, Semarang, 113 patients (76.4%) achieved optimal operation with a residu less than 2 cm, while 35 patients (23.6%) were not optimal with a residu more than 2 cm. FIGO stage (HR 2.44) and tumor residu (HR 2.15) were shown to be significant factors associated with the recurrence of epithelial ovarian cancer.

Conclusion: Overall disease-free survival in epithelial ovarian cancer at Dr. Kariadi Semarang were 74.8% (6 months), 57.1% (1 year), 42.5% (18 months), and 37.4% (2 years). Tumor residual factors and FIGO stage were shown to be significant prognostic factors influencing the recurrence of epithelial ovarian cancer.

 

Fulltext View|Download
Keywords: Epithelial ovarian cancer, Recurrence

Article Metrics:

Article Info
Section: Original Research Article
Language : EN
Recent articles
A Comparison of Wound Healing Score between Chromic Catgut and Polyglycolic Acid Perineal Suturing at Seven Days Postpartum: A Single Blind Randomized Controlled Trial The Association between Obstructive Sleep Apnea and Glycated Haemoglobin A1c (Hba1c) Level in Diabetes Mellitus Type II Patient Comparison of Saline Infusion Sonohisterography (SIS) and Histeroscopy Examination in Abnormal Uterine Bleeding More recent articles
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;1–41
  2. Berek JS, Hacker NF. Gynecologic Oncology Seventh Edition. 2021. 658– 686 p
  3. GLOBOCAN. Indonesia - Global Cancer Observatory. WHO; International Agency for Research on Cancer, 2018
  4. Kemenkes. Kementerian Kesehatan Republik Indonesia. Kementeri Kesehat RI. 2019;1:1
  5. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;280–304
  6. Berek JS, Berek DL. Berek & Novak ’ s Gynecology. In: Kluwer W, editor. 16th ed. Wolters Kluwer Health; 2020. p. 614–705
  7. Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672– 705
  8. van der Hel OL, Timmermans M, van Altena AM, Kruitwagen RFPM, Slangen BFM, Sonke GS, et al. Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989–2015. Eur J Cancer. 2019;118:97–104
  9. Khonsa O, Nuranna L, Sutrisna B. kesintasan pasien karsinoma ovarium dan faktor-faktor yang mempengaruhinya di RSUPN Dr. Cipto Mangunkusumo jakarta (pemantauan 5 tahun). inajog. 2007;8
  10. Institute national cancer. NCI Dictionary of Cancer Terms - National Cancer Institute
  11. Himoto Y, Cybulska P, Shitano F, Sala E, Zheng J, Capanu M, et al. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? Gynecol Oncol. 2019;155(2):192–200
  12. Chon HS, Sehovic M, Marchion D, Walko C, Xiong Y, Extermann M. Biologic mechanisms linked to prognosis in ovarian cancer that may be affected by aging. J Cancer. 2019;10(12):2604–18
  13. Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, et al. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021;161(3):693–9
  14. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res. 2012;5(7):901–10

Last update:

No citation recorded.

Last update:

No citation recorded.